Bharat Edition

Bharatstox

← All stocks

Lupin Ltd.

NSE: LUPIN · Healthcare

Sector

Healthcare

Size band

Large cap

Market cap

1,04,996cr

P/E

19.1

ROE

17.8%

Dividend yield

0.5%

No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.

Measured against

Operating margin30.0%
peer 20.5%
Revenue growth32.1%
peer 16.1%
Lupin Ltd.peer median

Peer set

Pharmaceuticals & Drugs · largest 12 of 82 measured at Q1 FY27 · financials via Screener

No guidance on record.

This section quotes what management told the market on the quarterly earnings call. We have not transcribed one for Lupin Ltd..

On air

20 calls · outcomes not tracked

Recorded as stated on air, with the analyst's SEBI registration status where it was given. Anchor calls carry no registration and are marked. Bharatstox does not make, endorse or repeat these calls, and none of them is our view.

Channel & showAiredStated targetStated stopOutcome
CNBC AwaazCNBC Awaax · no registration attached27 Aug+24.9%still open
NDTV ProfitNDTV Profit · no registration attached27 Aug+24.9%still open
NDTV ProfitNDTV Profit · no registration attached27 Aug-5.4%still open
CNBC AwaazCNBC Awaax · no registration attached27 Aug+24.9%still open
CNBC AwaazCNBC Awaax · no registration attached27 Aug+24.0%still open
CNBC AwaazCNBC Awaax · no registration attached27 Aug+24.7%still open
CNBC AwaazCNBC Awaax · no registration attached27 Aug+24.7%still open
CNBC AwaazCNBC Awaax · no registration attached27 Aug+24.4%still open
CNBC AwaazCNBC Awaax · no registration attached27 Aug+24.8%still open
CNBC AwaazCNBC Awaax · no registration attached27 Aug+25.3%still open
CNBC AwaazCNBC Awaax · no registration attached27 Augstill open
CNBC AwaazCNBC Awaax · no registration attached27 Aug+25.2%still open
CNBC AwaazCNBC Awaax · no registration attached27 Aug+25.5%still open
CNBC AwaazCNBC Awaax · no registration attached27 Aug+25.5%still open
CNBC AwaazCNBC Awaax · no registration attached27 Aug+26.0%still open
CNBC AwaazCNBC Awaax · no registration attached27 Aug+25.6%still open
Zee BusinessZee Business · no registration attached27 Aug-5.5%+17.1%still open
Zee BusinessZee Business · no registration attached27 Aug+24.8%still open
Zee BusinessZee Business · no registration attached27 Aug-6.0%still open
CNBC AwaazCNBC Awaax · no registration attached27 Aug-5.5%+17.1%still open

Filings

latest 25 of 543
  • General Updates28 Aug 2026
    Medium impactCredit RatingFiling PDF ↗
  • ESG Rating by Crisil ESG Ratings & Analytics Ltd.28 Aug 2026
    Medium impactCredit RatingFiling PDF ↗
  • Intimation of allotment of 30967 equity shares under ESOP.25 Aug 2026
    RoutineGeneralFiling PDF ↗
  • ESOP/ESOS/ESPS25 Aug 2026
    RoutineGeneralFiling PDF ↗
  • ESG Rating by ESG Risk Assessment and Insights Limited.24 Aug 2026
    RoutineGeneralFiling PDF ↗
  • General Updates24 Aug 2026
    RoutineGeneralFiling PDF ↗
  • VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.20 Aug 2026
    Medium impactInvestmentFiling PDF ↗
  • Arrangements for strategic, technical, manufacturing, or marketing tie up20 Aug 2026
    Medium impactCollaborationFiling PDF ↗
  • Intimation of Demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.18 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Demise18 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Press Release17 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Analysts/Institutional Investor Meet/Con. Call Updates12 Aug 2026
    RoutineResultsFiling PDF ↗
  • Press Release10 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Analysts/Institutional Investor Meet/Con. Call Updates10 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Analysts/Institutional Investor Meet/Con. Call Updates7 Aug 2026
    RoutineResultsFiling PDF ↗
  • Investor Presentation7 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Investor Presentation6 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Press Release6 Aug 2026
    RoutineResultsFiling PDF ↗
  • Outcome of Board Meeting6 Aug 2026
    RoutineBoard MeetingFiling PDF ↗
  • Shareholders meeting4 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Press Release31 Jul 2026
    RoutineGeneralFiling PDF ↗
  • Press Release31 Jul 2026
    RoutineGeneralFiling PDF ↗
  • Analysts/Institutional Investor Meet/Con. Call Updates22 Jul 2026
    RoutineResultsFiling PDF ↗
  • Acquisition21 Jul 2026
    Medium impactInvestmentFiling PDF ↗
  • Copy of Newspaper Publication14 Jul 2026
    RoutineGeneralFiling PDF ↗

The 25 most recent of 543 filings we hold for LUPIN, back to January 2024. Every filing, by day.

Disclaimer

Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Broadcast calls are reproduced as stated on air, attributed, with the analyst's SEBI registration status where given; they are not our calls and not our view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.

Bharat ke stocks, har subah.

One daily brief on what India's SEBI-registered research analysts are calling. No noise, no spam, unsubscribe whenever.